VOR BIOPHARMA INC
VOR BioPharma (VOR) is a clinical-stage biotechnology company focused on developing novel therapies for haematologic malignancies and related conditions. The business is small by market-cap standards (about $190m) and is driven primarily by clinical programmes, trial milestones and partnership or funding announcements. For investors that follow early-stage biotech, the attraction lies in potential upside from positive clinical data, but the company also carries considerable binary risk: trial results, regulatory decisions and financing needs can move the share price sharply. Financials for small biotech can be volatile and may require periodic capital raises, which can dilute existing holders. This summary is educational only and not personalised financial advice; investors should assess suitability against their risk tolerance, do their own diligence and consider seeking regulated advice before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VOR Biopharma’s stock with a target price of $40, indicating strong growth potential.
Financial Health
VOR BioPharma is generating strong cash flow, indicating good financial health and operational efficiency.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VOR
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
The company’s value is tied to trial progress and data readouts, which can create meaningful upside or downside depending on outcomes.
Catalysts to watch
Upcoming trial milestones, regulatory news and partnerships are potential share-price drivers, though results can be binary and unpredictable.
Finance & risks
As a small-cap biotech, VOR may need future fundraising that could dilute holdings; investors should weigh this alongside clinical risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
